Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
LONG-TERM TACRINE (COGNEX) TREATMENT - EFFECTS ON NURSING-HOME PLACEMENT AND MORTALITY
Autore:
KNOPMAN D; SCHNEIDER L; DAVIS K; TALWALKER S; SMITH F; HOOVER T; GRACON S; APTER JT; BARNETT M; BAUMEL B; EISNER LS; BENNETT D; FORCHETTI C; BLASS JP; BORISON RL; CELESIA GG; DEXTER J; DOODY R; DUBOFF EA; EARL NL; FARLOW M; HENDRIE HC; FARMER M; FERGUSON J; FOSTER NL; GREENWALD M; GROENENDYK A; JURKOWSKI C; KATZ I; PRODNER CK; KNOPMAN DS; MARGOLIN RA; MORRIS JC; RUBIN EH; REYES PF; RYMER MM; SADOWSKY CH; PAWLUCZYK S; SMITH WT; SOLOMON PR; PENDLEBURY WW; TAYLOR J; THEIN SG; TUTTLE P; TYNDALL RJ;
Indirizzi:
UNIV MINNESOTA,DEPT NEUROL,BOX 295 MINNEAPOLIS MN 55455 UNIV SO CALIF,DEPT PSYCHIAT LOS ANGELES CA 00000 MT SINAI SCH MED,DEPT PSYCHIAT NEW YORK NY 00000 PARKE DAVIS & CO,DEPT PHARMACEUT RES ANN ARBOR MI 00000 PRINCETON BIOMED RES PRINCETON NJ 00000 NEURO MED RES ASSOCIATES MIAMI FL 00000 RUSH ALZHEIMERS DIS CTR CHICAGO IL 60612 CORNELL UNIV,COLL MED,BURKE MED RES INST WHITE PLAINS NY 10605 DOWNTOWN VET AFFAIRS MED CTR,PSYCHIAT SERV AUGUSTA GA 00000 LOYOLA MED CTR MAYWOOD IL 00000 UNIV MISSOURI,HLTH SCI CTR,DEPT NEUROL COLUMBIA MO 00000 BAYLOR COLL MED,DEPT NEUROL HOUSTON TX 77030 CTR BEHAV MED WHEAT RIDGE CO 00000 MEMORY DISORDERS CLIN DURHAM NC 00000 INDIANA UNIV,CTR ALZHEIMERS DIS & RELATED DISORDERS INDIANAPOLIS IN 46204 CLIN STUDIES FLORIDA GERI ST PETERSBURG FL 00000 PHARMACOL RES CORP SALT LAKE CITY UT 00000 UNIV MICHIGAN,MED CTR,DEPT NEUROL ANN ARBOR MI 48109 SW INST CLIN RES RANCHO MIRAGE CA 00000 ENCINO MED PLAZA ALBUQUERQUE NM 00000 MEM HOSP BURLINGTON CTY,GERIATR ASSESSMENT PROGRAM MT HOLLY NJ 00000 MED COLL PENN & HAHNEMANN UNIV,DEPT PSYCHIAT PHILADELPHIA PA 19129 MED UNIV S CAROLINA CHARLESTON SC 29425 UNIV MINNESOTA,SCH MED,DEPT NEUROL MINNEAPOLIS MN 55455 VANDERBILT UNIV,MED CTR NASHVILLE TN 00000 WASHINGTON UNIV,SCH MED,ALZHEIMERS DIS RES CTR ST LOUIS MO 00000 THOMAS JEFFERSON UNIV,JEFFERSON MED COLL,DEPT NEUROL PHILADELPHIA PA 19107 CTR CLIN NEUROL STUDIES KANSAS CITY MO 00000 W PALM BEACH NEUROL GRP W PALM BEACH FL 00000 UNIV SO CALIF LOS ANGELES CA 00000 PACIFIC NW RES CTR PORTLAND OR 00000 SW VERMONT MED CTR,MEMORY DISORDERS CLIN BENNINGTON VT 00000 DEPT NEUROL RICHMOND VA 00000 PACIFIC RES NETWORK SAN DIEGO CA 00000 CAROLINA NEUROL CLIN CHARLOTTE NC 00000 KELLY CLIN TRIALS CTR SPRINGFIELD MO 00000
Titolo Testata:
Neurology
fascicolo: 1, volume: 47, anno: 1996,
pagine: 166 - 177
SICI:
0028-3878(1996)47:1<166:LT(T-E>2.0.ZU;2-S
Fonte:
ISI
Lingua:
ENG
Soggetto:
PRIMARY DEGENERATIVE DEMENTIA; ALZHEIMERS-DISEASE; CONTROLLED TRIAL; DOUBLE-BLIND; INSTITUTIONALIZATION; PREDICTORS; DEATH; SCALE;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Science Citation Index Expanded
Citazioni:
35
Recensione:
Indirizzi per estratti:
Citazione:
D. Knopman et al., "LONG-TERM TACRINE (COGNEX) TREATMENT - EFFECTS ON NURSING-HOME PLACEMENT AND MORTALITY", Neurology, 47(1), 1996, pp. 166-177

Abstract

Objective: To assess the possible association between tacrine (Cognex, manufactured by Parke-Davis, Morris Plains, NJ) dose and likelihood of nursing home placement (NHP) or death in patients with AD. Design: A 30-week, randomized, double-blind, placebo-controlled, parallel-group multicenter clinical trial involving 663 patients, after which patients were treated openly and followed up a minimum of 2 gears later. Patients: At baseline, outpatients were at least 50 years of age, met criteria for probable AD, with baseline Mini-Mental State Examination scores between 10 and 26 (inclusive), were otherwise healthy, and had a caregiver who could provide assessments and ensure medication compliance. Interventions: Randomized assignment to placebo or one of three ascending dosage regimens of tacrine over 30 weeks, followed by open label treatment for all patients who began the double-blind trial. Outcome measures: NHP and death were examined using logistic regression. Results: Patients who remained on tacrine and were receiving doses > 80 mg/d or, 120 mg/d were less likely to have entered a nursing home than patients on lower doses (odds ratios > 2.7, 2.8, respectively. ) There was a bend for lower mortality for patients receiving > 120 mg/d (p = 0.063). Conclusions: Treatment with tacrine at doses > 80 mg/d was associated with a reduced likelihood of NHP. These data demonstrate that tacrine's 30-week effects on cognitive function and clinicians' globalratings may generalize to effects on a major milestone of AD. Future studies should attempt to replicate these findings prospectively.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 15/07/20 alle ore 14:52:18